NASDAQ:VKTX - Viking Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.81 +0.10 (+0.85 %)
(As of 11/21/2018 09:54 AM ET)
Previous Close$11.71
Today's Range$11.81 - $12.00
52-Week Range$2.53 - $24.00
Volume1,045 shs
Average Volume3.86 million shs
Market Capitalization$833.22 million
P/E Ratio-14.87
Dividend YieldN/A
Beta2.92
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VKTX
Previous Symbol
CUSIPN/A
Phone858-704-4660

Debt

Debt-to-Equity RatioN/A
Current Ratio64.69
Quick Ratio64.69

Price-To-Earnings

Trailing P/E Ratio-14.87
Forward P/E Ratio-28.12
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.23 per share
Price / Book2.79

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,570,000.00
Net MarginsN/A
Return on Equity-15.82%
Return on Assets-15.14%

Miscellaneous

Employees14
Outstanding Shares71,460,000
Market Cap$833.22 million
OptionableOptionable

Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics Inc (NASDAQ:VKTX) issued its quarterly earnings data on Friday, November, 9th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. View Viking Therapeutics' Earnings History.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Viking Therapeutics.

What price target have analysts set for VKTX?

7 equities research analysts have issued 12-month price targets for Viking Therapeutics' shares. Their predictions range from $15.00 to $43.00. On average, they expect Viking Therapeutics' stock price to reach $28.00 in the next year. This suggests a possible upside of 137.1% from the stock's current price. View Analyst Price Targets for Viking Therapeutics.

What is the consensus analysts' recommendation for Viking Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics.

What are Wall Street analysts saying about Viking Therapeutics stock?

Here are some recent quotes from research analysts about Viking Therapeutics stock:
  • 1. Maxim Group analysts commented, "Viking reported 3Q18 with a net loss of ($6.6M) and ended the period with $304M in cash. We have increased expenses going forward as the NASH program moves into later-stage development and additional programs like 0214 move into the clinic." (11/8/2018)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $31 price target. Our peak sales estimates for VK2806 and VK5211 are based on our U.S. projections, and believe overall that peak sales could be conservative because of the size of the addressable markets, the continuing unmet medical need, and no projections for ex-U.S. sales currently. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (11/8/2018)

Has Viking Therapeutics been receiving favorable news coverage?

News coverage about VKTX stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Viking Therapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the next few days.

Are investors shorting Viking Therapeutics?

Viking Therapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 22,218,913 shares, an increase of 12.2% from the October 15th total of 19,809,519 shares. Based on an average daily volume of 2,924,213 shares, the short-interest ratio is currently 7.6 days. Currently, 40.3% of the company's stock are sold short. View Viking Therapeutics' Current Options Chain.

Who are some of Viking Therapeutics' key competitors?

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the folowing people:
  • Dr. Brian Lian, Pres, CEO & Director (Age 52)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 53)
  • Ms. Amy Broidrick, Sr. VP of Corp. Devel.
  • Dr. Hiroko Masamune, Chief Devel. Officer (Age 61)
  • Ms. Marianne Mancini, Sr. VP of Clinical Operations

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (11.91%), BlackRock Inc. (5.52%), Janus Henderson Group PLC (1.47%), Opaleye Management Inc. (1.15%), Jennison Associates LLC (0.90%) and Baker BROS. Advisors LP (0.59%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Ligand Pharmaceuticals Inc and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.

Which major investors are selling Viking Therapeutics stock?

VKTX stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Opaleye Management Inc., First Manhattan Co., EAM Investors LLC, Sio Capital Management LLC, GSA Capital Partners LLP, Virtu Financial LLC and Virtus ETF Advisers LLC. Company insiders that have sold Viking Therapeutics company stock in the last year include Ligand Pharmaceuticals Inc and Michael Morneau. View Insider Buying and Selling for Viking Therapeutics.

Which major investors are buying Viking Therapeutics stock?

VKTX stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, Baker BROS. Advisors LP, BlackRock Inc., Columbus Circle Investors, Nexthera Capital LP, Prosight Management LP and American Century Companies Inc.. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton and Lawson Macartney. View Insider Buying and Selling for Viking Therapeutics.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $11.81.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $833.22 million. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe.

What is Viking Therapeutics' official website?

The official website for Viking Therapeutics is http://www.vikingtherapeutics.com.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]


MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  388
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2018 by MarketBeat.com Staff

Featured Article: Fundamental Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel